{
  "label": "clinical_signal_03_ep_013",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:4f19c245d677c1fe3130a0d7489797849b719a5e5c06408f2c5455f12ba2dbc7",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:54:43.138448",
  "content": "## 2024-05-27 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 195\n- Active: 191\n- Screen Failures Cumulative: 29\n- Withdrawals Cumulative: 4\n\n#### Sites\n- Site 01 Enrolled: 19\n- Site 01 Active: 19\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 14\n- Site 02 Active: 14\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 18\n- Site 03 Active: 18\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 13\n- Site 04 Active: 13\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 16\n- Site 05 Active: 16\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 11\n- Site 06 Active: 11\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 21\n- Site 07 Active: 21\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 14\n- Site 08 Active: 14\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 16\n- Site 09 Active: 16\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 13\n- Site 10 Active: 13\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 18\n- Site 11 Active: 18\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 14\n- Site 12 Active: 14\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 52.4\n- ALT (U/L) Median: 50.8\n- AST (U/L) Mean: 45.0\n- AST (U/L) Median: 44.3\n- Bilirubin (mg/dL) Mean: 0.84\n- Bilirubin (mg/dL) Median: 0.82\n- ALP (U/L) Mean: 63.5\n- ALP (U/L) Median: 55.7\n- Creatinine (mg/dL) Mean: 0.83\n- Creatinine (mg/dL) Median: 0.85\n- BUN (mg/dL) Mean: 17.5\n- BUN (mg/dL) Median: 12.2\n- WBC (K/uL) Mean: 8.4\n- WBC (K/uL) Median: 5.7\n- Platelets (K/uL) Mean: 238\n- Platelets (K/uL) Median: 231\n\n#### Non-Statin Subgroup\n- N: 124\n- ALT (U/L) Mean: 20.7\n- ALT (U/L) Median: 20.4\n- AST (U/L) Mean: 18.1\n- AST (U/L) Median: 17.2\n- Bilirubin (mg/dL) Mean: 0.69\n- Bilirubin (mg/dL) Median: 0.66\n- ALP (U/L) Mean: 68.1\n- ALP (U/L) Median: 60.8\n- Creatinine (mg/dL) Mean: 0.84\n- Creatinine (mg/dL) Median: 0.88\n- BUN (mg/dL) Mean: 17.1\n- BUN (mg/dL) Median: 14.5\n- WBC (K/uL) Mean: 8.5\n- WBC (K/uL) Median: 5.6\n- Platelets (K/uL) Mean: 218\n- Platelets (K/uL) Median: 232\n\n### Adverse Events\n- AE ID: AE-0040, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0041, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0042, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0043, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0044, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 29\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-027, Description: Missed visit window (3 days late), Severity: minor, Site: site_01\n- PD ID: PD-028, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_08\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- All CRFs current through prior visit cycle\n- Statin co-administered cohort ALT mean 58 U/L; values remain below 2x ULN action threshold\n\n### Events\n- IP resupply shipped to Sites 06, 02\n- Site 10 monitoring visit completed, 2 findings\n\n### Notes\n- Week 13: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_013",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-05-27T10:00:00",
    "phase": "early_signal",
    "signal_density": "low",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}